Cargando…

Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study

Aim: To examine the effect of subthreshold micropulse yellow laser (SMYL) on best-corrected visual acuity (BCVA), central macular thickness (CMT), and optical coherence tomography angiography (OCT-A) changes in eyes with persistent diabetic macular edema (DME) after pars plana vitrectomy (PPV) for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonfiglio, Vincenza, Rejdak, Robert, Nowomiejska, Katarzyna, Zweifel, Sandrine Anne, Justus Wiest, Maximilian Robert, Romano, Giovanni Luca, Bucolo, Claudio, Gozzo, Lucia, Castellino, Niccolò, Patane, Clara, Pizzo, Corrado, Reibaldi, Michele, Russo, Andrea, Longo, Antonio, Fallico, Matteo, Macchi, Iacopo, Vadalà, Maria, Avitabile, Teresio, Costagliola, Ciro, Jonak, Kamil, Toro, Mario Damiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019565/
https://www.ncbi.nlm.nih.gov/pubmed/35462889
http://dx.doi.org/10.3389/fphar.2022.832448
_version_ 1784689314335031296
author Bonfiglio, Vincenza
Rejdak, Robert
Nowomiejska, Katarzyna
Zweifel, Sandrine Anne
Justus Wiest, Maximilian Robert
Romano, Giovanni Luca
Bucolo, Claudio
Gozzo, Lucia
Castellino, Niccolò
Patane, Clara
Pizzo, Corrado
Reibaldi, Michele
Russo, Andrea
Longo, Antonio
Fallico, Matteo
Macchi, Iacopo
Vadalà, Maria
Avitabile, Teresio
Costagliola, Ciro
Jonak, Kamil
Toro, Mario Damiano
author_facet Bonfiglio, Vincenza
Rejdak, Robert
Nowomiejska, Katarzyna
Zweifel, Sandrine Anne
Justus Wiest, Maximilian Robert
Romano, Giovanni Luca
Bucolo, Claudio
Gozzo, Lucia
Castellino, Niccolò
Patane, Clara
Pizzo, Corrado
Reibaldi, Michele
Russo, Andrea
Longo, Antonio
Fallico, Matteo
Macchi, Iacopo
Vadalà, Maria
Avitabile, Teresio
Costagliola, Ciro
Jonak, Kamil
Toro, Mario Damiano
author_sort Bonfiglio, Vincenza
collection PubMed
description Aim: To examine the effect of subthreshold micropulse yellow laser (SMYL) on best-corrected visual acuity (BCVA), central macular thickness (CMT), and optical coherence tomography angiography (OCT-A) changes in eyes with persistent diabetic macular edema (DME) after pars plana vitrectomy (PPV) for tractional DME (TDME). Patients and Methods: In a comparative study, 95 eyes of 95 consecutive patients with persistent DME were prospectively enrolled. The SMYL group (54 eyes) was treated with SMYL 6 months after PPV, while the control group (41 eyes) was followed up without treatment. BCVA and CMT by OCT were analyzed at baseline and 3 and 6 months. Additionally, parameters such as the vessel density (VD) in the superficial capillary plexus (SCP) and deep capillary plexus (DCP), respectively, and the area of the foveal avascular zone (FAZ) were also evaluated on OCT-A. Results: There were no significant differences between both groups in demographic data. In the SMYL group, mean BCVA was significantly increased [F(2,106) = 17.25; p < 0.001; [Formula: see text] = 0.246] from 51.54 ± 13.81 ETDRS letters at baseline to 57.81 ± 12.82 ETDRS letters at 3 months (p < 0.001) and 57.83 ± 13.95 EDTRS letters at 6 months (p < 0.001), respectively. In comparison to the control group, BCVA values were statistically significantly higher in the SMYL group at 3 and 6 months, respectively. Mean CMT significantly decreased [F(2,106) = 30.98; p < 0.001; [Formula: see text] = 0.368] from the baseline value 410.59 ± 129.91 μm to 323.50 ± 89.66 μm at 3 months (p < 0.001) and to 283.39 ± 73.45 μm at 6 months (p < 0.001). CMT values were significantly lower in the SMYL group (p < 0.001), especially at 6 months follow-up time (p < 0.001) compared with the control group. Parafoveal VD in the SCP and DCP was significantly higher in the SMYL group in comparison to the control group, respectively, at 3-month (SCP p < 0.001; DCP p < 0.001) and 6-month follow-up (SCP p < 0.001; DCP p < 0.001). FAZ area was also significantly smaller in the SMYL group at 6-month follow-up (p = 0.001). There were no adverse SMYL treatment effects. Conclusion: SMYL therapy may be a safe and effective treatment option in eyes with persistent macular edema following PPV for TDME.
format Online
Article
Text
id pubmed-9019565
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90195652022-04-21 Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study Bonfiglio, Vincenza Rejdak, Robert Nowomiejska, Katarzyna Zweifel, Sandrine Anne Justus Wiest, Maximilian Robert Romano, Giovanni Luca Bucolo, Claudio Gozzo, Lucia Castellino, Niccolò Patane, Clara Pizzo, Corrado Reibaldi, Michele Russo, Andrea Longo, Antonio Fallico, Matteo Macchi, Iacopo Vadalà, Maria Avitabile, Teresio Costagliola, Ciro Jonak, Kamil Toro, Mario Damiano Front Pharmacol Pharmacology Aim: To examine the effect of subthreshold micropulse yellow laser (SMYL) on best-corrected visual acuity (BCVA), central macular thickness (CMT), and optical coherence tomography angiography (OCT-A) changes in eyes with persistent diabetic macular edema (DME) after pars plana vitrectomy (PPV) for tractional DME (TDME). Patients and Methods: In a comparative study, 95 eyes of 95 consecutive patients with persistent DME were prospectively enrolled. The SMYL group (54 eyes) was treated with SMYL 6 months after PPV, while the control group (41 eyes) was followed up without treatment. BCVA and CMT by OCT were analyzed at baseline and 3 and 6 months. Additionally, parameters such as the vessel density (VD) in the superficial capillary plexus (SCP) and deep capillary plexus (DCP), respectively, and the area of the foveal avascular zone (FAZ) were also evaluated on OCT-A. Results: There were no significant differences between both groups in demographic data. In the SMYL group, mean BCVA was significantly increased [F(2,106) = 17.25; p < 0.001; [Formula: see text] = 0.246] from 51.54 ± 13.81 ETDRS letters at baseline to 57.81 ± 12.82 ETDRS letters at 3 months (p < 0.001) and 57.83 ± 13.95 EDTRS letters at 6 months (p < 0.001), respectively. In comparison to the control group, BCVA values were statistically significantly higher in the SMYL group at 3 and 6 months, respectively. Mean CMT significantly decreased [F(2,106) = 30.98; p < 0.001; [Formula: see text] = 0.368] from the baseline value 410.59 ± 129.91 μm to 323.50 ± 89.66 μm at 3 months (p < 0.001) and to 283.39 ± 73.45 μm at 6 months (p < 0.001). CMT values were significantly lower in the SMYL group (p < 0.001), especially at 6 months follow-up time (p < 0.001) compared with the control group. Parafoveal VD in the SCP and DCP was significantly higher in the SMYL group in comparison to the control group, respectively, at 3-month (SCP p < 0.001; DCP p < 0.001) and 6-month follow-up (SCP p < 0.001; DCP p < 0.001). FAZ area was also significantly smaller in the SMYL group at 6-month follow-up (p = 0.001). There were no adverse SMYL treatment effects. Conclusion: SMYL therapy may be a safe and effective treatment option in eyes with persistent macular edema following PPV for TDME. Frontiers Media S.A. 2022-04-06 /pmc/articles/PMC9019565/ /pubmed/35462889 http://dx.doi.org/10.3389/fphar.2022.832448 Text en Copyright © 2022 Bonfiglio, Rejdak, Nowomiejska, Zweifel, Justus Wiest, Romano, Bucolo, Gozzo, Castellino, Patane, Pizzo, Reibaldi, Russo, Longo, Fallico, Macchi, Vadalà, Avitabile, Costagliola, Jonak and Toro. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Bonfiglio, Vincenza
Rejdak, Robert
Nowomiejska, Katarzyna
Zweifel, Sandrine Anne
Justus Wiest, Maximilian Robert
Romano, Giovanni Luca
Bucolo, Claudio
Gozzo, Lucia
Castellino, Niccolò
Patane, Clara
Pizzo, Corrado
Reibaldi, Michele
Russo, Andrea
Longo, Antonio
Fallico, Matteo
Macchi, Iacopo
Vadalà, Maria
Avitabile, Teresio
Costagliola, Ciro
Jonak, Kamil
Toro, Mario Damiano
Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study
title Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study
title_full Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study
title_fullStr Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study
title_full_unstemmed Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study
title_short Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study
title_sort efficacy and safety of subthreshold micropulse yellow laser for persistent diabetic macular edema after vitrectomy: a pilot study
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019565/
https://www.ncbi.nlm.nih.gov/pubmed/35462889
http://dx.doi.org/10.3389/fphar.2022.832448
work_keys_str_mv AT bonfigliovincenza efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT rejdakrobert efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT nowomiejskakatarzyna efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT zweifelsandrineanne efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT justuswiestmaximilianrobert efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT romanogiovanniluca efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT bucoloclaudio efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT gozzolucia efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT castellinoniccolo efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT pataneclara efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT pizzocorrado efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT reibaldimichele efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT russoandrea efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT longoantonio efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT fallicomatteo efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT macchiiacopo efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT vadalamaria efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT avitabileteresio efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT costagliolaciro efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT jonakkamil efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy
AT toromariodamiano efficacyandsafetyofsubthresholdmicropulseyellowlaserforpersistentdiabeticmacularedemaaftervitrectomyapilotstudy